Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: neurodegenerative disease therapeutics - ProteoTech

Drug Profile

Research programme: neurodegenerative disease therapeutics - ProteoTech

Alternative Names: DP-68; DP-74; PD 61 W3; PeptiClere; PTI-19; PTI-51; PTI-51-CH3; Synuclere; TauPro

Latest Information Update: 22 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ProteoTech
  • Class Carbohydrates; Peptides; Small molecules
  • Mechanism of Action Alpha-synuclein inhibitors; Amyloid beta-protein inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Parkinson's disease
  • Discontinued Multiple system atrophy; Progressive supranuclear palsy

Most Recent Events

  • 22 Feb 2023 Discontinued - Preclinical for Multiple system atrophy in USA (unspecified route)
  • 22 Feb 2023 Discontinued - Preclinical for Progressive supranuclear palsy in USA (unspecified route)
  • 28 Apr 2019 No recent reports of development identified for preclinical development in Multiple system atrophy in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top